Action BIOA B BIOARCTIC AB
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues BioArctic AB

Actions

BIOA B

SE0010323311

Marché Fermé - Nasdaq Stockholm
Autres places de cotation
 17:29:39 17/05/2024 		Varia. 5j. Varia. 1 janv.
230,2 SEK -0,78 % Graphique intraday de BioArctic AB +13,40 % -14,04 %
17/05 Transcript : BioArctic AB, Q1 2024 Earnings Call, May 17, 2024
17/05 BioArctic AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Interim Report for the period January - March 2024
BioArctic AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Nordic Shares Moved Upward Wednesday; BioArctic Series B Topped Leaders
BioArctic, Eisai Launch Rolling US FDA Application for Leqembi's Maintenance Dosing
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March 2025)
Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing
Invitation to presentation of BioArctic's first quarter report for January - March 2024 on May 17 at 9:30 a.m. CET
BioArctic AB - Leqembi revenue totaled JPY 2.83 billion in the first quarter 2024
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
Nordic Stocks Closed Up Monday; Getinge Series B Climbed Highest
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802
Notice of Annual General Meeting in BioArctic AB (publ)
BioArctic publishes the Annual Report for 2023
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
Nordic Shares Moved Upward Monday; Invisio Led Increases
Nordic Stocks Rose Friday; BioArctic Series B Climbed Highest
BioArctic's focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BIOA B
  4. Actualités BioArctic AB
  5. Autres langues